San Francisco has sued major food companies like Coca-Cola and Nestle, accusing them of contributing to a public health crisis through the marketing and sale of ultraprocessed foods linked to diseases such as diabetes, cancer, and fatty liver disease, and seeking to curb their marketing practices and promote consumer awareness.
The demand for appetite suppressing anti-obesity drugs like Novo Nordisk's Wegovy presents opportunities for food manufacturers, despite an initial sell-off in shares of companies like Nestle. Investors believe that the market's reaction may be overdone, as the impact on long-term consumer habits is being extrapolated. While concerns exist about the potential impact on food sales, some investors see potential for major changes in the food and beverage industry, as well as other health-related stocks within the obesity industry. The limited availability of the drug and the development of companion products by food companies have led some investors to believe that the "miracle drugs" will not harm the industry in the long run. However, the affordability of these medications and the slow pace of behavior change may limit their widespread adoption.